Back to Subject Index | Return to Arthritis & Rheumatism Table of Contents Page

MA1, anti-apolipoprotein A1 in SLE and, 1655
Macromolecules, of stromelysin-1 and TIMP-1 in RA, 969
Macrophages
antiinflammatory effects of adenosine regulators and, 1040
autoimmune disease induction by microbial pathogens and, 458
Chlamydia trachomatis in synovial membrane and, 1410
clodronate-containing liposome in rat adjuvant arthritis and, 1777
guidelines for medical management of OA and, 1547
nuclear factor-κB, in rheumatoid synovium and, 1762
in RA, 384, 492, 1328
in sacroiliitis in AS, 499
TGFβ1 in hyaluronan synthesis in synovial lining cells and, 669
Magnetic resonance imaging (MRI)
in Baker's cyst of knee joint, 859
in DM, 68, 1513
joint and connective tissue ultrasonography and, 736
in localized synovial hemangioma, 559
in Lyme disease with symptoms of DM, 1157
PET and, in RA, 819
in rheumatoid synovitis, 1610
spin-spin relaxation of brain in SLE and, 810
Magnetic resonance spectroscopy, in DM, 68
Major basic protein, eosinophil, in SSc, 939
Major histocompatibility complex
class I, 458, 1547
class II, 1547, 1845
genes, 396, 1340
in RA, T cell receptors and, 577
Major outer membrane protein, Chlamydia trachomatis in synovial membrane and, 1410
Malignancy, cyclophosphamide and, in RA, 1120
Malpractice insurance, arthroscopy and, 1026
Mammalian studies
Lyme borreliosis, 565
Yersinia enterocolitica adhesin YadA in collagen, 1283
Mammary gland factor, cytokines, early response genes and, 877
Managed care organizations, rheumatology and, 451
Mannose-binding protein in SLE
deficiency of, 1713
gene polymorphism, 110
Marital status, number of children, low back pain and, 1232
Marrow infection, parvovirus B19 infection, chronic fatigue syndrome and, 638
Mast cells, in E-selectin in SSc, 406
Matrix
cartilage, protein, in relapsing polychondritis, 294
degradation, 173
extracellular, synovitis, protein clearance from canine knee and, 1085
mesangial, in glomerulonephritis and C4 deficiency, 1333
metalloproteinase, 574, 969, 1031, 1304, 1400, 1678
scintigraphic abnormalities, bone turnover and, in OA, 78
stromelysin degradation of cartilage and, 173, 1678
Maximum voluntary contractile force, MRI/MRS in DM and, 68
Mayo Clinic (Rochester, MN), epidemiology of polymyalgia rheumatica in Olmsted County, MN, 369
Medial tibiofemoral compartment, directed examination of, to predict cartilage abnormalities, 917
Medical care
cognitive deficit in rheumatic diseases and, 1363
in musculoskeletal conditions, 1128, 1351
Medical education
continuing, for primary care physicians in rheumatic disease, 533
rheumatology and, 451
student's perspective on RA and, 316
Medical management of OA, guidelines for
of hip, 1535
of knee, 1541
Medical Outcomes Study, Spanish outcome measures and, 1429
Medicare, morbidity in SLE and, 267
Medium vessel vasculitis, fatal, in lupus pregnancy, 710
MEDLINE literature searches, of active RA and AIDS, 1701
Mefenamic acid, in Chinese herbal medications, 614
Meharry Cohort Study, racial factors in gout and, 628
Membranous glomerulonephritis, renal biopsy in RA and, 242
Memory, cognitive deficit in rheumatic diseases and, 1363
Meniscal disease, guidelines for medical management of OA and, 1535
Meniscal tears, degenerative, monoclonal antibodies in detection of biochemical markers of, 655
Meniscectomy, partial lateral, CPPD synovitis in rabbit OA and, 201
Meniscus, knee and, 917, 953
Menopause, steroid and hormone replacement in postmenopausal RA bone metabolism, 901
Mental health, cognitive deficit in rheumatic diseases and, 1363
Mesangial glomerulonephritis, renal biopsy in RA and, 242
Mesangial matrix, in glomerulonephritis and C4 deficiency, 1333
Mesenchymal cells, immunosuppressive drugs during pregnancy and, 1722
Messenger RNA
cytokine, histologic findings in sacroiliitis in AS and, 499
IL-1 receptor antagonist in SLE and, 1055
in OA, 413, 420, 976, 1290
in RA, 96, 477, 678, 750, 976
in scleroderma in Tsk2 mouse, 1791
Metabolism
antiinflammatory effects of adenosine regulators and, 1040
in articular chondrocytes in the pathogenesis of arthritic swelling, 1529
bone, 902
cartilage, 655, 1085
in DM, 68
glucose, 819
in OA, 420, 525
in RA, 819, 902
Metacarpal joint, destruction of, in HIV infection with RA, 1328
Metacarpophalangeal joint, joint space measurement in hand by computerized image analysis, 891
Metalloproteinase
matrix, 574, 1031, 1304, 1400, 1678
1, in RA, 969, 1031
3, 1031
Methotrexate (MTX)
acute parvovirus B19-induced pancytopenia and, 1022
antiinflammatory effects of adenosine inhibitors and, 1040
in Cogan's syndrome, 1348
cytomegalovirus in, 1861
draft guidelines for drugs in JRA clinical trials and, 715
every-other-week, D24
hepatic toxicity induced by, in α1-antitrypsin deficiency, 1014
intramuscular, 575
long-term, 1194, 1865
low-dose, 291, 608
oral, 575
parenteral, shelf-life, cost and handling of, 575
patient information about, 874
during pregnancy, 1722
in RA, 29, 291, 297, 318, 326, 601, 819, 867, 1022, 1115, 1173, 1194, 1581, 1799, 1861, 1865
subcutaneous, 575
in Wegener's granulomatosis, 608
Methyl ester, nitro-L-arginine, lipoxin A4, nitric oxide and, in polymorphonuclear neutrophil vascular cytotoxicity, 768
Methylated bovine serum albumin
IL-1 and, in experimental arthritis in mice, 164
type II collagen in antigen-induced arthritis and, 1092
Methylsalicylate, guidelines for medical management of OA and, 1535
Methyltransferase, thiopurine, deficiency of, in azathioprine toxicity in RA, 142
Mi-2 autoantigen, in DM, 123, 1389
Microbial pathogens, autoimmune disease induction by, 458
Microcytotoxicity, anti-U1 RNA antibodies in connective tissue disease and, 1837
Micro-ELISA, cross-reactivity of anticardiolipin autoantibodies with oxidized low-density lipoprotein and, 1382
Microenvironment, spin-spin relaxation of brain in SLE and, 810
Microorganisms, Yersinia enterocolitica adhesion YadA in collagen and, 1283
Micropathology, spin-spin relaxation of brain in SLE and, 810
Microscopy
electron, 284, 485, 1194, 1618
immunoelectron, 678, 1410
light, 284, 1194, 1618
Microvascular perfusion, erythrocytes in rheumatoid vasculitis and, 248
Mimotopes, native 3-B-3, monoclonal antibodies in detection of biochemical markers of arthritis, 655
Minor labial salivary gland, E-selectin in, in SSc, 406
Minor lymphocyte-stimulating locus, autoimmune disease induction by microbial pathogens and, 458
Misoprostol, NSAID, gastrointestinal tract and, 5
Mitogens
CD28 cells in RA and, 649
chondrocytes in aging and development and, 960
Mixed connective tissue disease
autoimmune response to the spliceosome and, 777
HLA type and, 259
Mixed cryoglobulinemia, as possible preneoplastic disorder, 1859
Mls, autoimmune disease induction by microbial pathogens and, 458
Mobility
joint, guidelines for medical management of OA and, 1535
osteoporosis in RA and, 806
Modified Disease Activity Scores, in RA, 44
Modified Roenigk score, liver biopsy after MTX and, in RA, 1194
Molecular biology, evaluative laboratory testing and, 1555
Molecular diversity
IgG receptors in autoimmune disease and, 306
T cell receptors, RA and, 1242
Molecular immunology, immunosuppressive drugs during pregnancy and, 1722
Molecular mimicry
autoimmune disease induction by microbial pathogens and, 458
in Lyme borreliosis, 565
Molecular techniques, to study HLA-DR5 (DRB1*1201) in primary antiphospholipid syndrome in Mexican patients, 1340
Molecular weight
of B burgdorferi in Lyme borreliosis, 565
cytokines, early response genes and, 877
TGFβ1, hyaluronan synthesis in synovial lining cells and, 669
Monarthritis
chronic, hydatid disease in, 1338
knee, in pediatric Lyme arthritis in Europe, 361
Monarticular flares, stress fractures in RA and, 1025
Monkey studies, antigen-based heteropolymers, 190
Monoclonal antibodies
anti-CD3, 506, 649
anti-CD4, 1457, 1581, 1701
antigen-based heteropolymers and, 190
antiphospholipid, human, 1068
autoimmune sialadenitis in Sjogren's syndrome and, 1077
CAMPATH-1H, 254, 1187, 1242, 1589
CD4, 1097
chimeric, 1581
cross-reactivity of anticardiolipin autoantibodies with oxidized low-density lipoprotein and, 1382
in detection of biochemical markers of arthritis, 655
glycosaminoglycan epitopes in knee joint fluid after trauma and, 953
IgM[gl] KIM4.6, anti-DNA antibody binding and, 389
IL-1 in experimental arthritis in mice and, 164
in RA, 151, 254, 577, 649, 655, 1097, 1187, 1242, 1457, 1581, 1589, 1701
7-D-4, 655
in SLE, 506
to TGFβ1 in hyaluronan synthesis in synovial lining cells, 669
3-B-3, 655
Monoclonal anticardiolipin autoantibodies, cross-reactivity of, with oxidized low-density lipoprotein, 1382
Monocytes
cytokines, early response genes and, 877
HTLV-1 in PM and, 690
peripheral blood, IL-10 in synovial T cells and, 946
in RA, 384, 1046
in SLE, 1055, 1832
TGFβ1 in hyaluronan synthesis in synovial lining cells and, 669
Mononeuritis multiplex, in peripheral neuropathy with necrotizing vasculitis in RA, 1618
Mononuclear cells
blood, 477
cathepsin, collagenase and, in OA, 976
HTLV-1 in PM and, 690
infiltrates, 877, 1375, 1791
peripheral blood, 105, 485, 506, 577, 601, 877, 1771
in RA, 96, 477, 976, 1771
Mononuclear phagocytes, clodronate-containing liposomes, macrophages and, in rat adjuvant arthritis, 1777
Monosodium urate, bone marrow fat in inflammation in sickled erythrocytes and, 1349
Monospecific antisera, Ro and La antigens in human skin and, 1271
Monostotic Paget's disease of bone, quantitative bone scintigraphy in, 1506
Monozygotic twins
autoantibodies in SSc in, 1845
occurrence of AS in, in Finland, 381
osteoporosis in RA in, 806
Moods, cognitive deficit in rheumatic diseases and, 1363
Morbidity
functional disability in PM/DM and, 1218
risk factors for septic arthritis in joint disease and, 1819
socioeconomic predictors in SLE and, 267
walking velocity in elderly and, 343
Morning stiffness
in RA, 601, 819, 1107, 1568
sulfasalazine in spondylarthropathy and, 618
Morphologic abnormalities, parvovirus B19 infection, chronic fatigue syndrome and, 638
Morphologic lesions, renal biopsy in RA and, 242
Morphology
joint, in articular chondrocytes in the pathogenesis of arthritic swelling, 1529
Lyme borreliosis and, 565
in peripheral neuropathy with necrotizing vasculitis in RA, 1618
of substance P and calcitonin gene-related peptide in rat adjuvant arthritis, 699
Mortality
corticosteroids, pulse cyclophosphamide, plasma exchange and, in polyarteritis nodosa and Churg-Strauss syndrome, 1638
fatal pulmonary complication of lupus pregnancy, 710
guidelines for clinical trials in SSc and, 351
HLA type, MCTD and, 259
knee OA in the elderly and, 1500
NSAID and, 5, 1225
in peripheral neuropathy with necrotizing vasculitis in RA, 1618
in SLE, 267, 274, 1492
Motor deficits, in peripheral neuropathy with necrotizing vasculitis in RA, 1618
Mouse studies
See also BALB/c mice, CD-1 Swiss mice, HLA-B35 transgenic mice, HLA-B51 transgenic mice, MRL/lpr mice, Naive mice, (New Zealand white [times] BXSB)F1 mice, Nontransgenic mice, Tight skin mouse 2, Transgenic mice
anti-apolipoprotein A1 in SLE, 1655
antineutrophil cytoplasmic antibodies, 1375
autoimmune disease induction by microbial pathogens and, 458
bone marrow cell transplantation in antiphospholipid syndrome, 115
IL-1 and TNFα in RA, 151
MRL/lpr mice, autoimmune sialadenitis in Sjogren's syndrome, 1077
Mucocutaneous abnormalities, in SLE, 1475
Mucosa, NSAID, gastrointestinal tract and, 5
Mud-baths, hypothalamic-pituitary-adrenal axis dysregulation and, 724
Multifocal neuropathy, in peripheral neuropathy with necrotizing vasculitis in RA, 1618
Multifocal placoid pigment epitheliopathy, acute posterior, in systemic JRA, 446
Multi-infarct dementia, cognitive deficit in rheumatic diseases and, 1363
Multiple sclerosis, cytokines, early response genes and, 877
Multiplex amplification-refractory mutation restriction fragment length polymorphism, to study shared-epitope DRB1 alleles in RA, 1754
Murine air pouch, antiinflammatory effects of adenosine regulators and, 1040
Murine arthritis, IL-1 in, 164
Muscle
biopsy, 437, 690, 1157, 1513, 1618
deltoid, 1157
diseases of, inflammatory, HTLV-1 in PM and, 690
mass, osteoporosis in RA and, 806
MRI/MRS in DM and, 68
in walking velocity in elderly, 343
weakness, in Lyme disease with symptoms of DM, 1157
Musculoskeletal conditions
access to medical care in, 1128
cost and impact of, 1351
Musculoskeletal disability and deformity, cardiovascular health and fitness in end-stage OA, 799
Musculoskeletal disease, student's perspective on RA and, 315
Musculoskeletal involvement, in walking velocity in elderly, 343
Mutant DR molecules, site-directed, p4 peptide pocket binding to DRB1*0401 and, 1744
Mutations
COL2A1 gene, in chondrodysplasias and familial OA, 999
human monoclonal antiphospholipid antibody and, 1068
in scleroderma in Tsk2 mouse, 1791
Myalgia
cognitive deficit in eosinophilia-myalgia syndrome, 1363
in Lyme disease with symptoms of DM, 1157
in SLE, 1475
Mycobacteria, heat-killed,to study substance P and calcitonin gene-related peptide in rat adjuvant arthritis, 699
Mycobacterial arthritis, loosening of revision total hip replacement in RA and, 1315
Mycobacterium tuberculosis, total knee prosthesis and, 1325
Mycobacterium xenopi infection, CAMPATH-1H in refractory RA and, 1589
Mycoplasma pneumoniae, enteroviral RNA, bacterial DNA and, in juvenile DM, 1513
Myelitis, transverse, cognitive deficit in rheumatic diseases and, 1363
Myeloid precursors, cytokines, early response genes and, 877
Myeloma, spinal involvement in gout and, 139
Myeloperoxidase, antineutrophil cytoplasmic antibodies in SLE and, 633
Myocardial infarction, cross-reactivity of anticardiolipin autoantibodies with oxidized low-density lipoprotein and, 1382
Myofiber atrophy, HTLV-1 in PM and, 690
Myopathic DM, MRI/MRS in, 68
Myxoma, atrial, cutaneous PAN associated with Crohn's disease and, 1161